---
title: Effect of Selective and Nonselective Cyclooxygenase Enzyme Inhibition on Arterial Blood Pressure and Cerebral Blood Flow With Exposure to Intermittent Hypoxia in Humans
nct_id: NCT01280006
overall_status: COMPLETED
phase: PHASE1, PHASE2
sponsor: University of Calgary
study_type: INTERVENTIONAL
primary_condition: Obstructive Sleep Apnea
countries: Canada
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01280006.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01280006"
ct_last_update_post_date: 2011-12-05
last_seen_at: "2026-05-12T06:40:37.385Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Effect of Selective and Nonselective Cyclooxygenase Enzyme Inhibition on Arterial Blood Pressure and Cerebral Blood Flow With Exposure to Intermittent Hypoxia in Humans

**NCT ID:** [NCT01280006](https://clinicaltrials.gov/study/NCT01280006)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE1, PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 12
- **Lead Sponsor:** University of Calgary
- **Conditions:** Obstructive Sleep Apnea, Hypertension, Cardiovascular Diseases, Stroke
- **Start Date:** 2011-01
- **Completion Date:** 2011-12
- **CT.gov Last Update:** 2011-12-05

## Brief Summary

The study has been designed to assess the effect of cyclooxygenase inhibition on blood pressure, cerebral blood flow, ventilation and renal hemodynamics following chronic intermittent hypoxia exposure.

## Detailed Description

The study will specifically evaluate:

1. Cardiovascular effect of cyclooxygenase inhibitors on cerebral, vascular, blood pressure and homeostatic responses following chronic intermittent hypoxia exposure.
2. Ventilatory response of cyclooxygenase inhibitors following chronic intermittent hypoxia exposure
3. Evaluate the renal hemodynamic effect of chronic intermittent hypoxia exposure and cyclooxygenase inhibition.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 45 Years
- **Sex:** MALE
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Healthy male subjects
* 18 - 45 years of age
* Informed written consent

Exclusion Criteria:

* Any history of cardio-respiratory diseases, ongoing medication, smoking, trauma, acute illnesses, collagen vascular diseases, rheumatoid arthritis, osteoarthritis
```

## Interventions

- **Intermittent hypoxia** (OTHER) — The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. On the testing day, the subjects will undergo an acute intermittent hypoxia testing before and six hours of hypoxic chamber exposure mimicking obstructive sleep apnea syndrome.
- **Indomethacin** (DRUG) — The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.

Indomethacin: 50 mg, Oral, three times per day for five days.
- **Celecoxib** (DRUG) — The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.

Celecoxib: 200 mg, Oral, two times per day for five days with a visually matching sequential placebo in between of two doses.
- **Placebo** (DRUG) — The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.

Placebo: Oral, three times per day for five days.

## Primary Outcomes

- **Arterial Blood Pressure** _(time frame: Six weeks)_ — Blood pressure will be monitored during all three protocols.
- **Cerebral Blood Flow** _(time frame: Six weeks)_ — The cerebral blood flow will be mesauresed during each testing days of all three protocols.

## Secondary Outcomes

- **Ventilatory Response** _(time frame: Six weeks.)_
- **Renal Hemodynamics** _(time frame: Six weeks)_

## Locations (1)

- The Laboratory of Human Cerebrovascular Physiology, HMRB 209 & HMRB 230, University of Calgary, Calgary, Alberta, Canada

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.the laboratory of human cerebrovascular physiology, hmrb 209 & hmrb 230, university of calgary|calgary|alberta|canada` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01280006.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01280006*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*